Sertraline causes strong coronary vasodilation: Possible relevance for cardioprotection by selective serotonin reuptake inhibitors

Cardiovascular Drugs and Therapy

Volumn 18, Issue 6, 2004, Pages 441-447

  Van Melle, Joost P ^a   Buikema, Hendrik ^b   Van Den Berg, Maarten P ^a   Van Buiten, Azuwerus ^b   Van Veldhuisen, Dirk J ^a   Boonstra, Piet W ^a   Van Gilst, Wiek H ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Pharmacology; Sertraline; Smooth muscle relaxation; SSRI; Vasodilation

Indexed keywords

ANTIDEPRESSANT AGENT; PHENYLEPHRINE; POTASSIUM CHLORIDE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL TISSUE; AORTA; ARTICLE; CONCENTRATION RESPONSE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOLATED HEART; MALE; MAMMARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING; VASOCONSTRICTION;

ANIMALS; AORTA, THORACIC; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MAMMARY ARTERIES; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; VASODILATION;

EID: 16844362970     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-004-6221-3     Document Type: Article

References (24)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
2. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989;149:1785-1789.
3. Meijer WE, Heerdink ER, Leufkens HG, Herings RMC, Egberts ACG, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004;60:57-61.
4. Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: A prospective study. Lancet 2001;358:1766-1771.
5. Cohen ML, Wiley KS. Neuronal uptake inhibitors, nisoxetine and fluoxetine on rat vascular contractions. Eur J Pharmacol 1977;44:219-229.
6. Szabo C, Hardebo JE, Owman C. An amplifying effect of exogenous and neurally stored 5-hydroxytryptamine on the neurogenic contraction in rat tail artery. Br J Pharmacol 1991;102:401-407.
7. Gruetter CA, Lemke SM, Anestis DK, Szarek JL, Valentovic MA. Potentiation of 5-hydroxytryptamine-induced contraction in rat aorta by chlorpheniramine, citalopram and fluoxetine. Eur J Pharmacol 1992;217:109-118.
8. Ungvari Z, Pacher P, Kecskemeti V, Koller A. Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine, and a voltage-dependent Ca(2+) channel opener. Stroke 1999;30:1949-1954.
9. Becker B, Morel N, Vanbellinghen AM, Lebrun P. Blockade of calcium entry in smooth muscle cells by the antidepressant imipramine. Biochem Pharmacol 2004;68:833-842.
10. Wagenaar LJ, Voors AA, Buikema H, et al. Functional antagonism of different angiotensin II type I receptor blockers in human arteries. Cardiovasc Drugs Ther 2002;16:311-316.
11. Voors AA, Oosterga M, Buikema H, et al. Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. Cardiovasc Res 1997;34:568-574.
12. Buikema H, van Veldhuisen DJ, Hegeman H, van Gilst WH. Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: Effects of ibopamine and captopril. J Card Fail 1997;3:125-132.
13. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303-311.
14. Seabrook JM, Nolan PL. The vascular interaction of noradrenaline and 5-hydroxytryptamine. Eur J Pharmacol 1983;89:131-135.
15. Vila JM, Medina P, Segarra G, et al. Relaxant effects of antidepressants on human isolated mesenteric arteries. Br J Clin Pharmacol 1999;48:223-229.
16. +]i. J Cardiovasc Pharmacol 2000;35:849-854.
17. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: A double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51:18-27 (suppl B).
18. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987;41:1051-1064.
19. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
20. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.
21. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: Findings from a double-blind, placebo-controlled trial. Psychosom Med 2000;62:783-789.
22. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898.
23. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-36.
24. Serebruany VL, Classman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-944.